<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548145</url>
  </required_header>
  <id_info>
    <org_study_id>OSK-07098</org_study_id>
    <nct_id>NCT00548145</nct_id>
  </id_info>
  <brief_title>The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease</brief_title>
  <acronym>PIT-ROAD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Osaka University</source>
  <brief_summary>
    <textblock>
      Some studies suggest that statin medications may be effective against Alzheimer's disease.
      However, this has not been proven. The purpose of this study is to evaluate the efficacy of
      pitavastatin in patients with mild to moderate Alzheimer's disease and hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PIT-ROAD study will include 50 patients who have taken donepezil more than 3 months
      stably. This study will see how the use of a particular statin medication, pitavastatin,
      affects ADAS-Jcog score etc. and cholesterol.

      Participants will be given a full information of the study and written informed consent
      should be obtained before entering the study. Participants will take part in 5 visits over
      the course of 12 months. If participants have taken cholesterol lowering drug, they will have
      wash-out period at least 4weeks. Participants will undergo 8 tests (ADAS-Jcog etc., baseline
      and month 12 visits), complete a medical history questionnaire (baseline), complete
      medication side effect review through questionnaire and/or blood sample (all visits).
      Participants will be randomly assigned to receive either pitavastatin or other cholesterol
      lowering medication for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog)</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Alzheimer's Disease Assessment Scale-cognitive component-Japanese version is a cognitive test for Alzheimer's disease. This test includes some aspects that assess memory ,orientation, language, praxis, and so on. The possible range of this test is 0-70 points.Higher total points indicate more impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMSE, Neuropsychiatric Inventory, GDS-15, Zarit Burden Scale, Physical Self-Maintenance Scale, IADL, Everyday Memory Checklist, TC, HDL-C, Non HDL-C*, Apo A1, Apo B, Apo E *: Non HDL-C = (TC) - (HDL-C)</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Mini-Mental State Examination(MMSE),Geriatric Depression Scale-15(GDS-15),Instrumental Activities of Daily Living Scale(IADL),Total Cholesterol(TC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>2 mg by orally/day Duration: 12 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)</intervention_name>
    <description>duration: 12 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alzheimer's Disease patients (15 ≤ MMSE total score ≤ 23, CDR &quot;1&quot; or &quot;2&quot;)

          -  Patients with hypercholesterolemia

          -  Patients who have taken donepezil more than 3 months stably

          -  Both patients and care-givers must be more than 20 years old

        Exclusion Criteria:

          -  Women with pregnancy or breast-feeding

          -  Malignant tumor

          -  Cerebrovascular disorder or myocardial infarction prior to 12 weeks

          -  Heart failure [New York Heart Association (NYHA) class III or IV]

          -  Hepatic or renal dysfunction

          -  Severe hypertension

          -  Hypothyroidism, hereditary muscular disease, history of drug-induced myopathy

          -  Current involvement in another investigational drug study

          -  Alcoholism, drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Kazui, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.med.osaka-u.ac.jp/pub/psy/www/en/index.html</url>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2007</study_first_posted>
  <results_first_submitted>December 28, 2011</results_first_submitted>
  <results_first_submitted_qc>May 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2012</results_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka University</investigator_affiliation>
    <investigator_full_name>Hiroaki Kazui</investigator_full_name>
    <investigator_title>M.D.Ph.D</investigator_title>
  </responsible_party>
  <keyword>Pitavastatin</keyword>
  <keyword>Statins</keyword>
  <keyword>Donepezil</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>ADAS-Jcog</keyword>
  <keyword>Alzheimer Disease (MMSE 15-23 and CDR1 or 2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Hyperlipidemia patients with mild to moderate Alzheimer’s disease(MMSE15～23)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pitavastatin</title>
          <description>2 mg by orally/day Duration: 12 months</description>
        </group>
        <group group_id="P2">
          <title>Cholesterol-lowering Medicine Other Than Statin</title>
          <description>duration: 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pitavastatin</title>
          <description>2 mg by orally/day Duration: 12 months</description>
        </group>
        <group group_id="B2">
          <title>Cholesterol-lowering Medicine Other Than Statin</title>
          <description>duration: 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.8" spread="7.2"/>
                    <measurement group_id="B2" value="75.3" spread="7.7"/>
                    <measurement group_id="B3" value="75.5" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog)</title>
        <description>Alzheimer's Disease Assessment Scale-cognitive component-Japanese version is a cognitive test for Alzheimer's disease. This test includes some aspects that assess memory ,orientation, language, praxis, and so on. The possible range of this test is 0-70 points.Higher total points indicate more impairment.</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin</title>
            <description>2 mg by orally/day Duration: 12 months</description>
          </group>
          <group group_id="O2">
            <title>Cholesterol-lowering Medicine Other Than Statin</title>
            <description>duration: 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog)</title>
          <description>Alzheimer's Disease Assessment Scale-cognitive component-Japanese version is a cognitive test for Alzheimer's disease. This test includes some aspects that assess memory ,orientation, language, praxis, and so on. The possible range of this test is 0-70 points.Higher total points indicate more impairment.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.59" spread="6.13"/>
                    <measurement group_id="O2" value="19.50" spread="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.20" spread="9.31"/>
                    <measurement group_id="O2" value="20.59" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MMSE, Neuropsychiatric Inventory, GDS-15, Zarit Burden Scale, Physical Self-Maintenance Scale, IADL, Everyday Memory Checklist, TC, HDL-C, Non HDL-C*, Apo A1, Apo B, Apo E *: Non HDL-C = (TC) - (HDL-C)</title>
        <description>Mini-Mental State Examination(MMSE),Geriatric Depression Scale-15(GDS-15),Instrumental Activities of Daily Living Scale(IADL),Total Cholesterol(TC)</description>
        <time_frame>baseline and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pitavastatin</title>
          <description>2 mg by orally/day Duration: 12 months</description>
        </group>
        <group group_id="E2">
          <title>Cholesterol-lowering Medicine Other Than Statin</title>
          <description>duration: 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hiroaki Kazui,Ph.D.</name_or_title>
      <organization>Osaka University Hospital</organization>
      <phone>81-6-6879-3051</phone>
      <email>kazui@psy.med.osaka-u.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

